Xeljanz/Xeljanz XR (Tofacitinib/Tofacitinib XR), an Oral JAK Inhibitor, Now Approved for Adults with Active Psoriatic Arthritis
Although psoriatic arthritis most often affects the distal joints in the fingers and toes, the disease can also affect the lower back, wrists, knees, and ankles.
In this trial, treatment with apremilast showed significantly greater improvement in American College of Rheumatology 20% (ACR20) improvement response criteria and Health Assessment Questionnaire Disability Index (HAQ-DI) scores at week 16 for 20- and 30-mg twice-daily doses compared with placebo (Wells AF, et al. Rheumatology. 2018 Apr 4. Epub ahead of print).
Results 1 - 2 of 2